Effectiveness of COVID-19 Vaccines Against Omicron Variant

Campos, Daniel Melo de Oliveira; Silva, Maria Karolaynne da; Oliveira, Cláudio Bruno Silva de; Fulco, U. L.

doi:10.2217/imt-2022-0077

Cited by 7 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different studies have shown that CoronaVac and Moderna (mRNA‐1273) and Pfizer/BioNTech (BNT162b2) mRNA vaccines have significantly decreased neutralizing activity against the Omicron variant (Lineage B.1.1.529). 160 …”

Section: Vaccine Studies For Covid‐19 Diseasementioning

confidence: 99%

“…On the other hand, a third dose of the Pfizer‐BioNTech (BNT162b2) vaccine has been shown to neutralize the Omicron variant (Lineage B.1.1.529). Different studies have shown that CoronaVac and Moderna (mRNA‐1273) and Pfizer/BioNTech (BNT162b2) mRNA vaccines have significantly decreased neutralizing activity against the Omicron variant (Lineage B.1.1.529) 160 …”

Section: Vaccine Studies For Covid‐19 Diseasementioning

confidence: 99%

“…TA B L E 4 COVID-19 vaccines approved by at least one country. 106 Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, shown that CoronaVac and Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) mRNA vaccines have significantly decreased neutralizing activity against the Omicron variant (Lineage B.1.1.529) 160.…”

mentioning

confidence: 99%

See 2 more Smart Citations

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies

Polatoğlu

Öncü‐Öner

Dalman

et al. 2023

MedComm

View full text Add to dashboard Cite

Coronavirus Disease‐19 (COVID‐19) is an infectious disease caused by severe acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and transmissible coronavirus. Most cases of COVID‐19 have mild to moderate symptoms, including cough, fever, myalgias, and headache. On the other hand, this coronavirus can lead to severe complications and death in some cases. Therefore, vaccination is the most effective tool to prevent and eradicate COVID‐19 disease. Also, rapid and effective diagnostic tests are critical in identifying cases of COVID‐19. The COVID‐19 pandemic has a dynamic structure on the agenda and contains up‐to‐date developments. This article has comprehensively discussed the most up‐to‐date pandemic situation since it first appeared. For the first time, not only the structure, replication mechanism, and variants of SARS‐CoV‐2 (Alpha, Beta, Gamma, Omicron, Delta, Epsilon, Kappa, Mu, Eta, Zeta, Theta, lota, Lambda) but also all the details of the pandemic, such as how it came out, how it spread, current cases, what precautions should be taken, prevention strategies, the vaccines produced, the tests developed, and the drugs used are reviewed in every aspect. Herein, the comparison of diagnostic tests for SARS‐CoV‐2 in terms of procedure, accuracy, cost, and time has been presented. The mechanism, safety, efficacy, and effectiveness of COVID‐19 vaccines against SARS‐CoV‐2 variants have been evaluated. Drug studies, therapeutic targets, various immunomodulators, and antiviral molecules applied to patients with COVID‐19 have been reviewed.

show abstract

Section: Vaccine Studies For Covid‐19 Diseasementioning

confidence: 99%

Section: Vaccine Studies For Covid‐19 Diseasementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies

Polatoğlu

Öncü‐Öner

Dalman

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Questions remain regarding booster vaccination and waning immunity, duration of immunity, and heterologous vaccination Fiolet et al (2021) . In addition, the emergence of SARS-CoV-2 variants could jeopardize the global impact of mass vaccination campaigns, because it is already known that the natural tendency toward high mutation rates is the reason for the failure of most vaccines against viruses Zuin et al, 2021 , de Oliveira Campos et al, 2022 . After Alpha, Beta, Gamma, and Delta variants, the most recent variant of concern (VOC) is the Omicron (B.1.1.529), which has evolved due to the accumulation of a high number of mutations, particularly in the spike protein, raising concerns that it is capable of evading pre-existing immunity acquired through vaccination or natural infection.…”

Section: Introductionmentioning

confidence: 99%

Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants

Campos

Silva

Barbosa

et al. 2022

Computational Biology and Chemistry

Self Cite

View full text Add to dashboard Cite

“…La probabilidad se expresa en porcentajes genéticamente, información que puede ser de utilidad para el clínico y el tomador de decisiones al momento de establecer conductas y políticas de salud. Pero también es una realidad que la efectividad depende del tipo de variante, en este estudio se asume que la variante corresponde a Ómicron, pero es una suposición epidemiológica que no se comprobó objetivamente [16,17,18]. Acta Med Peru.…”

unclassified

Efectividad de la vacuna para SARS-CoV-2 sobre hospitalizaciones por COVID-19 durante la cuarta ola epidémica en Querétaro, México

Villarreal Ríos,

Hernández García,

Dávalos Álvarez

et al. 2023

Acta Med Peru

View full text Add to dashboard Cite

Objetivo. Determinar la vacunación como factor protector para hospitalización en paciente con COVID-19 en la cuarta ola de la pandemia. Métodos. Diseño de cohorte retrospectiva en pacientes con COVID-19 durante la cuarta ola (1 enero a 9 febrero de 2022). Grupos expuestos, antecedente de vacuna anti COVID-19 (vacuna de adenovirus modificado genéticamente y vacuna de ácido ribonucleico mensajero), grupo no expuestos, no vacuna. Tamaño de muestra todos los casos del periodo, grupo expuesto (vacuna de adenovirus modificados genéticamente, n=41; vacuna de ácido ribonucleico mensajero, n=105; y grupo no expuesto, n=263. Análisis estadístico, chi cuadrada, riesgo relativo, regresión logística múltiple y cálculo de probabilidad de ocurrencia del evento. Resultados. En una mujer entre 50 y 59 años que no tiene enfermedad crónica degenerativa y que recibió vacuna de adenovirus modificado genéticamente, la probabilidad de hospitalización si presenta COVID-19 es 34,5%; si recibió vacuna de acido ribonucleico mensajero la probabilidad de hospitalización es 1,7% y si no recibió vacuna la probabilidad de hospitalización varía entre 56,6% y 58,9%. Esta misma mujer si presenta enfermedad crónica degenerativa la probabilidad de hospitalización es 50,3% con vacuna de adenovirus modificado genéticamente, 4,4% con vacuna de ácido ribonucleico mensajero, y varía entre 73,4% y 77,2% si no recibió vacuna. Conclusiones. La vacuna anti COVID-19 es un factor protector para hospitalización en pacientes que presentan cuadro agudo de COVID-19.

show abstract

Effectiveness of COVID-19 Vaccines Against Omicron Variant

Cited by 7 publications

References 13 publications

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies

Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants

Efectividad de la vacuna para SARS-CoV-2 sobre hospitalizaciones por COVID-19 durante la cuarta ola epidémica en Querétaro, México

Contact Info

Product

Resources

About